← FDA DRUG APPROVALS

FDA NDA · NDA214047

THYQUIDITY

levothyroxine sodium

Sponsor: STEVENS J

APPLICATION
NDA214047
TYPE
NDA
ORIGINAL APPROVAL
2020-11-30
LATEST ACTION
2020-11-30
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

THYQUIDITY · ReferencePrescription
LEVOTHYROXINE SODIUM 100MCG/5ML · SOLUTION · ORAL

Approval history

2020-11-30Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →